Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.64
+0.12501.66%
Volume:1.05M
Turnover:7.90M
Market Cap:1.67B
PE:-5.40
High:7.68
Open:7.50
Low:7.38
Close:7.51
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.53
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:3.21
PE(LYR):-5.38

Loading ...

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on Axpaxli™ Nda With Submission Planned for Fourth Quarter 2026

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix - to Conduct Interim Sol-R Safety Analysis in Q4 2026

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix - Sol-R Trial to Remain Masked Through Week 96; Topline Results Expected Q1 2028

THOMSON REUTERS
·
Jun 17

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:40 AM

Reuters
·
Jun 17

Ocular Therapeutix Expands Equity Plan and Confirms Leadership

TIPRANKS
·
Jun 13

Ocular Therapeutix - Appoints Jason Robins as Chief Financial Officer on June 10, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 13

Ocular Therapeutix names Jason Robins CFO, replacing interim role

Reuters
·
Jun 13

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Jun 08

BRIEF-Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 05

Ocular Therapeutix grants inducement awards of options for 51,775 shares, RSUs for 16,950 shares to new hires

Reuters
·
Jun 05

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 04

Ocular Therapeutix to host investor day with retinal disease experts

Reuters
·
Jun 02

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

GlobeNewswire
·
Jun 02

Ocular Therapeutix Insiders Make a Wave of High-Level Stock Moves

TIPRANKS
·
May 29

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

Simply Wall St.
·
May 20

Ocular Therapeutix grants new HR chief options for 75,000 shares, 25,000 RSUs

Reuters
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 15

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14